Jasper Therapeutics

JSPR

Market cap $51.5M

NEW YORK, Nov. 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors Driven Brands Holdings, Inc. (NASDAQ: DRVN) and Jasper Therapeutics, Inc (NASDAQ:JSPR) on behalf of long-term stockholders. More information about each potential case can be found at the link provided.

New York, New York--(Newsfile Corp. - November 18, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"), of the important November 18, 2025 lead plaintiff deadline. SO WHAT: If you purchased Jasper Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) and certain of its officers.

NEW YORK--(BUSINESS WIRE)---- $JSPR #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR) and reminds investors of the November 18, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

LOS ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of JSPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

New York, New York--(Newsfile Corp. - November 17, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"), of the important November 18, 2025 lead plaintiff deadline. SO WHAT: If you purchased Jasper Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Jasper to Contact Him Directly to Discuss Their Options If you purchased or acquired securities in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - November 17, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR) and reminds investors of the November 18, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming November 18, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR) securities between November 30, 2023 and July 3, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON JASPER THERAPEUTICS, INC. (JSPR), CLICK HERE TO PARTICIP.

NEW YORK, Nov. 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the “Class Period”), of the important November 18, 2025 lead plaintiff deadline.

New York, New York--(Newsfile Corp. - November 16, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"), of the important November 18, 2025 lead plaintiff deadline. SO WHAT: If you purchased Jasper Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.